The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Johnson & Johnson expands access in Europe for dual-energy THERMOCOOL SMARTTOUCH SF cardiac ablation platform
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 25, 5:06 AM EDT

Johnson & Johnson expands access in Europe for dual-energy THERMOCOOL SMARTTOUCH SF cardiac ablation platform

The company said its Dual Energy THERMOCOOL SMARTTOUCH SF platform is now available in Europe, aiming to broaden access to advanced catheter-based treatment for certain cardiac rhythm disorders.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Johnson & Johnson said it is advancing cardiac ablation technology in Europe by making its Dual Energy THERMOCOOL SMARTTOUCH SF platform available in the region. The announcement, dated June 25, 2026, frames the move as an expansion of availability for a system designed for catheter-based treatment of abnormal heart rhythms, a procedure commonly used to address conditions such as atrial fibrillation.

Cardiac ablation is a minimally invasive procedure in which a clinician threads a catheter through blood vessels to the heart and uses energy to create small controlled lesions that interrupt misfiring electrical indicates. By using an energy-based approach, ablation seeks to restore more normal rhythm and reduce reliance on long-term medication for some patients, though outcomes can vary by patient characteristics and the specific clinical pathway.

In this case, J&J’s platform description centers on “dual energy.” In practical terms, dual-energy systems are intended to give physicians multiple modes of energy delivery during an ablation workflow, rather than restricting treatment to a single energy type. The Dual Energy THERMOCOOL SMARTTOUCH SF platform is positioned as an integrated solution within that category, with the THERMOCOOL SMARTTOUCH SF branding indicating it is part of the company’s broader SMARTTOUCH family of ablation products.

The company’s European availability announcement does not provide detailed information in the posted item about which specific countries are included, what timelines apply in each market, or the exact clinical indications tied to the platform’s use. It also does not disclose sales figures, expected revenue impact, pricing, or adoption targets, limiting what can be concluded about near-term financial significance.

The significance of expanding availability in Europe for device companies is often tied to regulatory coverage, distribution and hospital penetration, and the competitive dynamics of electrophysiology equipment. Europe is a major market for cardiac rhythm management, and ablation technologies are a key area of spending for hospitals that perform electrophysiology procedures, including specialized cardiac centers.

Even without additional disclosure, expanding access to a named ablation platform suggests J&J is pushing its installed base and procedural footprint. Hospitals that already stock and train on related catheter technology may be more likely to adopt an upgraded platform if it fits existing workflow, training, and supply chains. For patients, broader availability can be meaningful if it reduces delays in access to particular procedural options.

Still, important details are not contained in the announcement item: it does not specify the regulatory status in each European market, does not detail any clinical evidence or comparative data, and does not describe what is new versus prior generations in the product line. It also does not clarify whether the “dual energy” aspect is delivered through different energy settings, different catheter configurations, or other system-level components.

Going forward, investors and clinicians may look for additional information on (1) which European markets the platform reaches first, (2) whether J&J highlights any procedural outcomes or clinical study results connected to the dual-energy capability, and (3) how quickly adoption occurs among electrophysiology centers relative to competing ablation systems. For now, the company’s public statement is best read as a distribution and availability milestone rather than a detailed performance update.

Why It Matters

  • Expanding availability of a dual-energy ablation platform can influence how quickly hospitals and electrophysiology centers adopt specific catheter-based treatment options.
  • Cardiac ablation is a core procedure within cardiac rhythm management, so availability milestones can affect competitive positioning among medical device makers.
  • The lack of disclosed commercial and regulatory specifics leaves uncertainty about how broad and fast the rollout will be across Europe.

Sources

Key Facts

  • Johnson & Johnson said it has advanced cardiac ablation technology in Europe by making its Dual Energy THERMOCOOL SMARTTOUCH SF platform available there.
  • The announcement is dated June 25, 2026, and was published via Yahoo Finance.
  • The platform is described as a “Dual Energy” ablation solution within the THERMOCOOL SMARTTOUCH SF product line.
  • The posting does not include disclosed country-by-country launch timing, pricing, or financial expectations.

Healthcare Related

Johnson & Johnson expands access in Europe for dual-energy THERMOCOOL SMARTTOUCH SF cardiac ablation platform | The Apex Times